Literature DB >> 33885715

SARS-CoV-2 Transmission Risk Among National Basketball Association Players, Staff, and Vendors Exposed to Individuals With Positive Test Results After COVID-19 Recovery During the 2020 Regular and Postseason.

Christina D Mack1, John DiFiori2, Caroline G Tai1, Kristin Y Shiue1, Yonatan H Grad3, Deverick J Anderson4, David D Ho5, Leroy Sims6, Christopher LeMay6, Jimmie Mancell7, Lisa L Maragakis8.   

Abstract

Importance: Clinical data are lacking regarding the risk of viral transmission from individuals who have positive reverse-transcription-polymerase chain reaction (RT-PCR) SARS-CoV-2 test results after recovery from COVID-19. Objective: To describe case characteristics, including viral dynamics and transmission of infection, for individuals who have clinically recovered from SARS-CoV-2 infection but continued to have positive test results following discontinuation of isolation precautions. Design, Setting, and Participants: This retrospective cohort study used data collected from June 11, 2020, to October 19, 2020, as part of the National Basketball Association (NBA) closed campus occupational health program in Orlando, Florida, which required daily RT-PCR testing and ad hoc serological testing for SARS-CoV-2 IgG antibodies. Nearly 4000 NBA players, staff, and vendors participated in the NBA's regular and postseason occupational health program in Orlando. Persistent positive cases were those who recovered from a documented SARS-CoV-2 infection, satisfied US Centers for Disease Control and Prevention criteria for discontinuation of isolation precautions, and had at least 1 postinfection positive RT-PCR test(s) result. Exposures: Person-days of participation in indoor, unmasked activities that involved direct exposure between persistent positive cases and noninfected individuals. Main Outcomes and Measures: Transmission of SARS-CoV-2 following interaction with persistent positive individuals, as measured by the number of new COVID-19 cases in the Orlando campus program.
Results: Among 3648 individuals who participated, 36 (1%) were persistent positive cases, most of whom were younger than 30 years (24 [67%]) and male (34 [94%]). Antibodies were detected in 33 individuals (91.7%); all remained asymptomatic following the index persistent positive RT-PCR result. Cycle threshold values for persistent positive RT-PCR test results were typically above the Roche cobas SARS-CoV-2 limit of detection. Cases were monitored for up to 100 days (mean [SD], 51 [23.9] days), during which there were at least 1480 person-days of direct exposure activities, with no transmission events or secondary infections of SARS-CoV-2 detected (0 new cases). Conclusions and Relevance: In this retrospective cohort study of the 2020 NBA closed campus occupational health program, recovered individuals who continued to test positive for SARS-CoV-2 following discontinuation of isolation were not infectious to others. These findings support time-based US Centers of Disease Control and Prevention recommendations for ending isolation.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33885715      PMCID: PMC8063131          DOI: 10.1001/jamainternmed.2021.2114

Source DB:  PubMed          Journal:  JAMA Intern Med        ISSN: 2168-6106            Impact factor:   21.873


  9 in total

1.  Case Report: Assessing COVID-19 Transmission in Professional Volleyball in Germany, September to December 2020: An Epidemiological Study.

Authors:  Oliver Morath; Friedrich Barsch; Adhara Lazaro; Daniela Huzly; Peter Deibert
Journal:  Front Sports Act Living       Date:  2022-06-14

Review 2.  SARS-CoV-2 Transmission and Prevention in the Era of the Delta Variant.

Authors:  Eric A Meyerowitz; Aaron Richterman
Journal:  Infect Dis Clin North Am       Date:  2022-02-01       Impact factor: 5.905

3.  Public health implications of opening National Football League stadiums during the COVID-19 pandemic.

Authors:  Bernardo García Bulle; Dennis Shen; Devavrat Shah; Anette E Hosoi
Journal:  Proc Natl Acad Sci U S A       Date:  2022-03-22       Impact factor: 12.779

4.  The required size of cluster randomized trials of nonpharmaceutical interventions in epidemic settings.

Authors:  Justin K Sheen; Johannes Haushofer; C Jessica E Metcalf; Lee Kennedy-Shaffer
Journal:  Stat Med       Date:  2022-03-07       Impact factor: 2.497

5.  SARS-CoV-2 transmission risk screening for safer social events: a non-randomised controlled study.

Authors:  Rafel Ramos; Lia Alves-Cabratosa; Jordi Blanch; Àlex Pèlach; Laura Albert; Quirze Salomó; Sílvia Cabarrocas; Marc Comas-Cufí; Ruth Martí-Lluch; Anna Ponjoan; Maria Garcia-Gil; Salomé de Cambra; Albert d'Anta; Elisabet Balló; Albert Alum; Rosa Núria Aleixandre
Journal:  Sci Rep       Date:  2022-07-27       Impact factor: 4.996

6.  COVID-19 in European Soccer: A Public 2-Year Comparison of COVID-19 Case Management and Case Characteristics between the 1st Bundesliga, La Liga, Serie A and the Premier League.

Authors:  Jan-Niklas Droste; Robert Percy Marshall; Stephan Borte; Sebastian Seyler; Helge Riepenhof
Journal:  Life (Basel)       Date:  2022-08-11

7.  Viral dynamics of acute SARS-CoV-2 infection and applications to diagnostic and public health strategies.

Authors:  Stephen M Kissler; Joseph R Fauver; Christina Mack; Scott W Olesen; Caroline Tai; Kristin Y Shiue; Chaney C Kalinich; Sarah Jednak; Isabel M Ott; Chantal B F Vogels; Jay Wohlgemuth; James Weisberger; John DiFiori; Deverick J Anderson; Jimmie Mancell; David D Ho; Nathan D Grubaugh; Yonatan H Grad
Journal:  PLoS Biol       Date:  2021-07-12       Impact factor: 9.593

8.  Asymptomatic infection is the pandemic's dark matter.

Authors:  David N Fisman; Ashleigh R Tuite
Journal:  Proc Natl Acad Sci U S A       Date:  2021-09-21       Impact factor: 11.205

9.  Association between household exposure and cycle threshold in COVID-19 infected health care workers.

Authors:  Ai Chien; Sandra Domeracki; Sandeep Guntur; Kristopher Taylor; Chuanyi M Lu; Harry Lampiris; Paul D Blanc
Journal:  J Occup Med Toxicol       Date:  2021-08-04       Impact factor: 2.646

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.